{
  "docId": "019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "docSlug": "0f1a880702ed9ddf7f6316bb24fc6717",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 37,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide highlights the synergy between two existing therapies (TVI and Olvi-Vec) to create a new modality.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-d25f-763f-9eab-9ec8cb3a6b5e/21",
  "deckHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "deckJsonHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e.json",
  "deckAnchorHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy. Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunostimulatory. Anticipated to enhance effect of neoantigen specific effector T cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ff674ad-a541-41cc-90d7-39bb134c67d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.62,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. Vaccination increases the numbers of neoantigen-specific T cells in the body and Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue receptivity to adoptively transferred neoantigen-specific effector T cells.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9de8f54a-7051-4d7d-ba1c-7e86968c572b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.62,
        "x": 0.35,
        "y": 0.74
      },
      "kind": "source-note",
      "text": "Novel IO modality: United States Patent No. 11,633,442, issued in April 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "880f03a4-935a-4454-b87d-c19c7db70bfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.62,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "table",
      "text": "Technology: TVI Adoptive Cell Therapy, Olvi-Vec Oncolytic Immunotherapy. Patients Dosed: ~130, ~150. Regulatory: Fast Track Designation / FDA Grant - glioblastoma, Phase 3 enrolling - ovarian",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad93bbf3-cc58-42fe-b296-c3c731533cc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b25d90-3f69-4e55-9fc2-513ce627d6f6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c31634f5-1a07-4d2c-b840-72cce223f7dd",
      "evidence": "V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}